AGIO
Agios Pharmaceuticals, Inc.NASDAQHealthcare$35.20-1.14%ClosedMarket Cap: $2.06B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.70
P/S
37.74
EV/EBITDA
-4.54
DCF Value
$-22.71
FCF Yield
-18.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
88.3%
Operating Margin
-873.9%
Net Margin
-764.0%
ROE
-31.1%
ROA
-31.8%
ROIC
-38.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $20.0M | 96.9% | $-121.6M | $-108.0M | $-1.85 | — |
| FY 2025 | $54.0M | 88.3% | $-472.1M | $-412.8M | $-7.12 | — |
| Q3 2025 | $12.9M | 87.0% | $-116.9M | $-103.4M | $-1.78 | — |
| Q2 2025 | $12.5M | 76.2% | $-127.1M | $-112.0M | $-1.93 | — |
| Q1 2025 | $8.7M | 87.6% | $-106.6M | $-89.3M | $-1.55 | — |
| Q4 2024 | $10.7M | 88.3% | $-125.0M | $-96.5M | $-1.69 | — |
| FY 2024 | $36.5M | 88.6% | $-425.7M | $673.7M | $11.64 | — |
| Q3 2024 | $9.0M | 91.3% | $-102.8M | $947.9M | $16.22 | — |
| Q2 2024 | $8.6M | 64.2% | $-105.8M | $-96.1M | $-1.69 | — |
| Q1 2024 | $8.2M | 75.9% | $-92.1M | $-81.5M | $-1.45 | — |
| Q4 2023 | $7.1M | 72.0% | $-106.3M | $-95.9M | $-1.72 | — |
| FY 2023 | $26.8M | 64.6% | $-391.5M | $-352.1M | $-6.33 | — |